Clinical Trials Logo

Clinical Trial Summary

The purpose of this research is to assess the safety profile and clinical benefit of Awar-Awar leaf active fraction as a complementary therapy in chemotherapy of stage IV breast cancer


Clinical Trial Description

The study uses a double blind design and randomized controlled trial that compares the safety and clinical efficacy profiles of 3 treatment groups (each consists of 97 subjects who received chemotherapy for 6 cycles). The treatment group was given FADA at a dose of 800 mg/day and 2000 mg/day compared to the placebo group. Interim analysis is carried out after 25% of the subjects completed 3 cycles of chemotherapy; whereas interim analysis II is carried out after 50% of the subjects completed 3 cycles of chemotherapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05033925
Study type Interventional
Source Gadjah Mada University
Contact Nanang Fakhrudin, Ph.D
Phone +62 85878502778
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date September 7, 2021
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT03304210 - PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer Phase 1
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) Phase 1/Phase 2
Recruiting NCT03401359 - The Resistance and Immune Response to Palbociclib in Breast Cancer N/A
Recruiting NCT03870919 - Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients N/A
Completed NCT00393341 - Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer N/A
Recruiting NCT04566458 - RWD Study in HER2+ mBC Patients in Third-Line Therapy
Recruiting NCT04697043 - The Benefit of Surgery in Stage IV of Breast Cancer N/A
Recruiting NCT04123704 - Sitravatinib in Metastatic Breast Cancer Phase 2
Active, not recruiting NCT03339765 - Self-Advocacy Serious Game in Advanced Cancer N/A
Recruiting NCT03324425 - Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer Phase 2
Terminated NCT03202446 - Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer Phase 3
Active, not recruiting NCT02448771 - A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer Phase 1/Phase 2
Recruiting NCT03045289 - A Whole-food, Plant-Based Nutrition Intervention in Women With Metastatic Breast Cancer N/A
Recruiting NCT04752059 - Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases Phase 2
Not yet recruiting NCT04896320 - Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer. Phase 1/Phase 2
Recruiting NCT04852081 - Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Completed NCT04133207 - Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine Therapy
Recruiting NCT04628806 - Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells
Recruiting NCT05036252 - Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity